vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs 13.3%, a 2.9% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -10.9%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-74.1M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
AMPH vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $208.0M |
| Net Profit | $24.4M | $33.9M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 19.1% |
| Net Margin | 13.3% | 16.3% |
| Revenue YoY | -1.8% | -10.9% |
| Net Profit YoY | -35.7% | -14.2% |
| EPS (diluted) | $0.51 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $208.0M | ||
| Q3 25 | $191.8M | $216.4M | ||
| Q2 25 | $174.4M | $210.5M | ||
| Q1 25 | $170.5M | $217.9M | ||
| Q4 24 | $186.5M | $233.5M | ||
| Q3 24 | $191.2M | $227.0M | ||
| Q2 24 | $182.4M | $224.4M | ||
| Q1 24 | $171.8M | $222.0M |
| Q4 25 | $24.4M | $33.9M | ||
| Q3 25 | $17.4M | $31.3M | ||
| Q2 25 | $31.0M | $42.7M | ||
| Q1 25 | $25.3M | $28.1M | ||
| Q4 24 | $38.0M | $39.5M | ||
| Q3 24 | $40.4M | $49.1M | ||
| Q2 24 | $37.9M | $26.0M | ||
| Q1 24 | $43.2M | $37.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 19.1% | ||
| Q3 25 | 13.2% | 21.7% | ||
| Q2 25 | 24.2% | 21.5% | ||
| Q1 25 | 21.9% | 16.8% | ||
| Q4 24 | 24.2% | 21.7% | ||
| Q3 24 | 29.8% | 24.3% | ||
| Q2 24 | 30.3% | 19.7% | ||
| Q1 24 | 27.9% | 14.5% |
| Q4 25 | 13.3% | 16.3% | ||
| Q3 25 | 9.0% | 14.5% | ||
| Q2 25 | 17.8% | 20.3% | ||
| Q1 25 | 14.8% | 12.9% | ||
| Q4 24 | 20.4% | 16.9% | ||
| Q3 24 | 21.1% | 21.6% | ||
| Q2 24 | 20.8% | 11.6% | ||
| Q1 24 | 25.1% | 17.1% |
| Q4 25 | $0.51 | $5.15 | ||
| Q3 25 | $0.37 | $4.65 | ||
| Q2 25 | $0.64 | $6.12 | ||
| Q1 25 | $0.51 | $4.05 | ||
| Q4 24 | $0.74 | $4.65 | ||
| Q3 24 | $0.78 | $5.71 | ||
| Q2 24 | $0.73 | $2.43 | ||
| Q1 24 | $0.81 | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $390.0M |
| Stockholders' EquityBook value | $788.8M | $934.0M |
| Total Assets | $1.6B | $4.3B |
| Debt / EquityLower = less leverage | 0.77× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $390.0M | ||
| Q3 25 | $608.6M | $390.6M | ||
| Q2 25 | $607.7M | $231.3M | ||
| Q1 25 | $603.9M | $231.7M | ||
| Q4 24 | $601.6M | $232.1M | ||
| Q3 24 | $596.4M | $237.5M | ||
| Q2 24 | $586.9M | $247.6M | ||
| Q1 24 | $594.0M | $253.0M |
| Q4 25 | $788.8M | $934.0M | ||
| Q3 25 | $776.7M | $918.7M | ||
| Q2 25 | $757.5M | $896.4M | ||
| Q1 25 | $751.3M | $893.7M | ||
| Q4 24 | $732.3M | $897.5M | ||
| Q3 24 | $727.7M | $889.0M | ||
| Q2 24 | $713.3M | $868.7M | ||
| Q1 24 | $672.4M | $871.7M |
| Q4 25 | $1.6B | $4.3B | ||
| Q3 25 | $1.7B | $3.9B | ||
| Q2 25 | $1.6B | $3.7B | ||
| Q1 25 | $1.6B | $3.7B | ||
| Q4 24 | $1.6B | $4.0B | ||
| Q3 24 | $1.5B | $3.6B | ||
| Q2 24 | $1.5B | $3.6B | ||
| Q1 24 | $1.6B | $3.5B |
| Q4 25 | 0.77× | 0.42× | ||
| Q3 25 | 0.78× | 0.43× | ||
| Q2 25 | 0.80× | 0.26× | ||
| Q1 25 | 0.80× | 0.26× | ||
| Q4 24 | 0.82× | 0.26× | ||
| Q3 24 | 0.82× | 0.27× | ||
| Q2 24 | 0.82× | 0.29× | ||
| Q1 24 | 0.88× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-67.2M |
| Free Cash FlowOCF − Capex | $24.6M | $-74.1M |
| FCF MarginFCF / Revenue | 13.4% | -35.6% |
| Capex IntensityCapex / Revenue | 4.5% | 3.3% |
| Cash ConversionOCF / Net Profit | 1.35× | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-67.2M | ||
| Q3 25 | $52.6M | $108.3M | ||
| Q2 25 | $35.6M | $75.8M | ||
| Q1 25 | $35.1M | $-3.8M | ||
| Q4 24 | $29.0M | $1.8M | ||
| Q3 24 | $60.0M | $69.1M | ||
| Q2 24 | $69.1M | $70.0M | ||
| Q1 24 | $55.3M | $-34.5M |
| Q4 25 | $24.6M | $-74.1M | ||
| Q3 25 | $47.2M | $106.9M | ||
| Q2 25 | $25.0M | $74.2M | ||
| Q1 25 | $24.4M | $-6.8M | ||
| Q4 24 | $16.6M | $-3.8M | ||
| Q3 24 | $46.2M | $68.7M | ||
| Q2 24 | $63.1M | $68.6M | ||
| Q1 24 | $46.5M | $-36.5M |
| Q4 25 | 13.4% | -35.6% | ||
| Q3 25 | 24.6% | 49.4% | ||
| Q2 25 | 14.3% | 35.2% | ||
| Q1 25 | 14.3% | -3.1% | ||
| Q4 24 | 8.9% | -1.6% | ||
| Q3 24 | 24.1% | 30.3% | ||
| Q2 24 | 34.6% | 30.6% | ||
| Q1 24 | 27.1% | -16.4% |
| Q4 25 | 4.5% | 3.3% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 6.3% | 1.4% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.6% | ||
| Q1 24 | 5.1% | 0.9% |
| Q4 25 | 1.35× | -1.99× | ||
| Q3 25 | 3.03× | 3.45× | ||
| Q2 25 | 1.15× | 1.77× | ||
| Q1 25 | 1.39× | -0.13× | ||
| Q4 24 | 0.76× | 0.04× | ||
| Q3 24 | 1.48× | 1.41× | ||
| Q2 24 | 1.82× | 2.69× | ||
| Q1 24 | 1.28× | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
